Press Releases

INOVIO Completes Enrollment of Phase 1B Clinical Trial for its DNA Vaccine Candidate Against Lassa Fever, INO-4500, in West Africa

Posted on October 26, 2021

INOVIO Announces Collaboration with Colombia; Memorandum of Understanding Focuses on Protecting Against COVID-19 and Supporting Broader Health Preparedness Initiatives

Posted on October 21, 2021

INOVIO Announces Online Preprint Publication of Homologous Boosting Data for its COVID-19 DNA Vaccine Candidate, INO-4800

Posted on October 12, 2021

INOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization

Posted on October 11, 2021

INOVIO to Present Three Posters at IDWeek 2021

Posted on September 29, 2021

INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico

Posted on September 22, 2021

INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800

Posted on August 26, 2021

INOVIO Reports Second Quarter 2021 Financial Results

Posted on August 9, 2021

INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO’s COVID-19 DNA Vaccine Candidate

Posted on August 9, 2021

INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine Against Middle East Respiratory Syndrome (MERS), a Coronavirus Disease

Posted on August 4, 2021

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.